Bristol Myers Squibb: Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus

Deucravacitinib showed statistically significant efficacy at primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI(4)) responses versus placebo at Week 32 Secondary endpoints

Related Keywords

Copenhagen ,Køavn ,Denmark ,Australia ,Monash ,South Australia ,Japan ,Jonathan Sadeh ,Bristol Myers Squibb ,Ericf Morand ,Instagram ,Linkedin ,Monash University ,Twitter ,Bristol Myers Squibb Company ,Japan Ministry Of Health ,Head Of The School Clinical Sciences ,Facebook ,Fibrosis Development ,European Medical Association ,Drug Administration ,European Alliance Of Associations ,Exchange Commission ,Youtube ,British Isles Lupus Assessment Group ,Systemic Lupus International Collaborating Clinics ,Systemic Lupus Erythematosus ,Myers Squibb ,European Alliance ,Clinical Sciences ,Lupus Low Disease Activity State ,Cutaneous Lupus Erythematosus Disease Area ,Severity Index ,Bristol Myers ,Isles Lupus Assessment Group ,Composite Lupus Assessment ,Severity Index Activity ,Pioneering Paths Forward ,Transform Patient ,Juno Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Bristol ,Myers ,Squibb ,Gate ,Breaking ,Data ,Wular ,022 ,Emonstrate ,Deucravacitinib ,Ignificantly ,Mproved ,Disease ,Activity ,Hase ,Paisley ,Study ,Systemic ,Lupus ,Rythematosus ,